Onco Actu du 5 novembre 2019

	2.13 ETIOLOGIE - NDMA
FDA: Zantac carcinogens no more dangerous than 'grilled or smoked meats' [Fierce Pharma] Drugmakers may be recalling the heartburn med Zantac around the world, but the FDA wants consumers to stop worrying.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
E-cigarettes aren't a 'gateway' to teen smoking, study says [CNN] The new research, published Monday in the medical journal Nicotine and Tobacco Research, suggests any relationship between teenage vaping and smoking can be attributed to shared risk factors for tobacco use -- for example, whether an adolescent drinks alcohol or is surrounded by smokers.
	3.2 PRÉVENTION - OBÉSITÉ
How Washington keeps America sick and fat [Politico] Many researchers, policymakers and public health advocates interviewed by POLITICO said that the complexity of nutrition research factors into its low priority in Washington, which isn’t exactly known for having a long attention span.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Men over 40 with BRCA2 gene fault ‘should get regular PSA screening’ [Institute of Cancer Research] At the conference – the UK’s biggest cancer meeting – the ICR researchers presented findings from the IMPACT study, which assessed the potential benefits of PSA testing in men with BRCA2 mutations at 65 centres in 20 different countries around the world.
	4.11 DÉP., DIAG. & PRONO. - OVAIRE
Blood test can help GPs spot ovarian cancer in women with suspicious symptoms [NCRI] Although the CA125 test is already in use in countires around the world, this is the first large study to look at how well it performs in general practice for testing women who have possible symptoms of ovarian cancer.
	4.12 BIOPSIES LIQUIDES
AI blood test can spot signs of brain tumour to speed up diagnosis [NCRI] The researchers tried out the new test on blood samples taken from 400 patients with possible signs of brain tumour who had been referred for a brain scan at the Western General Hospital in Edinburgh, UK. Of these, 40 were subsequently found to have a brain tumour. Using the test, the researchers were able to correctly identify 82% of brain tumours. The test was also able to correctly identify 84% of people who did not have brain tumours, meaning it had a low rate of ‘false positives.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
ACP issues guidance for colorectal cancer screening [American College of Physicians] Physicians should screen for colorectal cancer in average-risk adults who do not have symptoms between the ages of 50 and 75, the American College of Physicians (ACP) states in a new evidence-based guidance statement published in the journal Annals of Internal Medicine.
	4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
Cervical screening: DIY alternative to smear test 'promising' [BBC News] Dr Nedjaj said the S5 test needed to be tried on more than 10,000 women before it could be offered on the NHS. She predicted the at-home tests could be available via the health service in five years.
Cervical pre-cancer can be detected in self-collected urine or vaginal samples Results of study are a ‘game changer’ for screening [NCRI] “We found that the S5 classifier with or without HPV testing worked well in both urine and vaginal samples,” said Dr Nedjai. “It distinguished between women who had no pre-cancerous lesions and those who had CIN3 or higher lesions.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
A molecular strategy that helps prevent tumour formation in mice described [CNIO] Researchers around the world are studying the potential of FASN to treat certain types of cancer. However, the results of the CNIO team suggest that its effectiveness is preventive, not therapeutic.
	5.10 TRAITEMENTS - ESSAIS
Antibody-Drug Conjugate Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [AACR] ADCT-402 combines a potent DNA-damaging agent called pyrrolobenzodiazepine (PBD) with a monoclonal antibody directed against CD19.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Trends in clinical development for PD-1/PD-L1 inhibitors [Nature Reviews Drug Discovery] Since 2006, 3,362 trials have been launched to test PD-1/PD-L1 mAbs alone or in combination with other agents, and 2,975 of them are still active as of September 2019, planning to recruit over 500,000 patients.
	5.17 TRAITEMENTS - RADIOTHÉRAPIE
Revolutionising radiotherapy: making a cornerstone cancer treatment more personal and powerful [Cancer Research UK] CRUK RadNet members are investigating resistance from a number of angles, looking at ways to overcome the fact that radiotherapy can’t destroy certain cancers. They’re particularly focusing on the cancer types where survival is still depressingly low, like pancreatic cancer and brain tumours.
	5.2.3 PHARMA - ÉCONOMIE
AstraZeneca wins kudos for pipeline turnaround in a new ranking of the top 10 R&D players in the biopharma world [EndPoints] Soriot was tapped for the top job 7 years ago, when the company’s rep in R&D had hit rock bottom and was widely considered the worst in Big Pharma. He’s made a lot of changes along the way, and had his share of setbacks. But it paid off.
	5.2.4 PHARMA - HALOZYME
Halozyme kills pipeline, cuts 55% of jobs as lead cancer med flops in phase 3 [Fierce Biotech] The new Halozyme will move forward with 120 employees. The move is expected to save the company between $130 million and $140 million in 2020 and make it a “sustainably profitable company” starting in the second quarter of 2020.
Halozyme laying off 160 after pancreatic cancer trial comes up short [Biopharma Dive] The company will focus on its drug-delivery technology, which has been applied to drugs like Herceptin to convert them from intravenous to subcutaneous administration.
Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3 [Xconomy] With PEGPH20 development now halted, Halozyme says it will close its oncology operations and lay off approximately 160 people—roughly 55 percent of its workforce.
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint [Halozyme] While there was a higher response rate in the PEGPH20 treatment arm, this did not translate into an improvement in duration of response, Progression Free Survival or Overall Survival.
Halozyme's lead drug flops in PhIII, forcing CEO to ax 160 and reset focus on tech platform [EndPoints] This isn’t the first failure for this drug, A little more than 2 years ago the biotech reported another fail in pancreatic cancer when it was combined with Folfirinox.
	5.2.5 PHARMA - AVEO
FDA tells Aveo no, again, for tivozanib as biotech tries to find yet another path forward [Fierce Biotech] Remarkably, given the FDA ordeal, the drug was actually approved in Europe based on TIVO-1 back in 2017 under the name Fotivda, though this hinged on the outcome of TIVO-3.
Aveo's cancer drug runs into a skeptical FDA [Biopharma Dive] Tivozanib's hazard ratio for overall survival is the critical statistic to watch, with the company conceding in a Monday release that it would withdraw the New Drug Application if the final analysis results in a hazard ratio above one.
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma [Aveo] The FDA noted that the Company’s current interim OS results do not abrogate the FDA’s concerns over detriment and that those results may worsen with final analysis at 263 events, and that the median OS for tivozanib is worse than that of sorafenib.
FDA to Aveo: That's still a 'no' on tivo. Aveo: We'll be back. [EndPoints] Aveo said it will narrow its proposed indication to relapsed/refractory renal cell carcinoma, with plans to submit an NDA in the first quarter of 2020.
	6.11 PATIENTS
For some cancer patients, monitoring symptoms can extend their lives [Washington Post] But there are challenges to putting these benefits in practice.